Literature DB >> 12719318

Methylprednisolone for acute spinal cord injury: not a standard of care.

Herman Hugenholtz1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12719318      PMCID: PMC153684     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  23 in total

1.  Consequences of high-dose steroid therapy for acute spinal cord injury.

Authors:  S J Gerndt; J L Rodriguez; J W Pawlik; P A Taheri; W L Wahl; A J Micheals; S M Papadopoulos
Journal:  J Trauma       Date:  1997-02

Review 2.  High dose methylprednisolone in the management of acute spinal cord injury - a systematic review from a clinical perspective.

Authors:  D J Short; W S El Masry; P W Jones
Journal:  Spinal Cord       Date:  2000-05       Impact factor: 2.772

3.  Steroids and spinal cord injury: revisiting the NASCIS 2 and NASCIS 3 trials.

Authors:  S Nesathurai
Journal:  J Trauma       Date:  1998-12

Review 4.  The neuroprotective pharmacology of methylprednisolone.

Authors:  E D Hall
Journal:  J Neurosurg       Date:  1992-01       Impact factor: 5.115

5.  Methylprednisolone or naloxone treatment after acute spinal cord injury: 1-year follow-up data. Results of the second National Acute Spinal Cord Injury Study.

Authors:  M B Bracken; M J Shepard; W F Collins; T R Holford; D S Baskin; H M Eisenberg; E Flamm; L Leo-Summers; J C Maroon; L F Marshall
Journal:  J Neurosurg       Date:  1992-01       Impact factor: 5.115

6.  Methylprednisolone for acute spinal cord injury: an inappropriate standard of care.

Authors:  R J Hurlbert
Journal:  J Neurosurg       Date:  2000-07       Impact factor: 5.115

7.  A critical appraisal of the reporting of the National Acute Spinal Cord Injury Studies (II and III) of methylprednisolone in acute spinal cord injury.

Authors:  W P Coleman; D Benzel; D W Cahill; T Ducker; F Geisler; B Green; M R Gropper; J Goffin; P W Madsen; D J Maiman; S L Ondra; M Rosner; R C Sasso; G R Trost; S Zeidman
Journal:  J Spinal Disord       Date:  2000-06

8.  Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study.

Authors:  M B Bracken; M J Shepard; T R Holford; L Leo-Summers; E F Aldrich; M Fazl; M Fehlings; D L Herr; P W Hitchon; L F Marshall; R P Nockels; V Pascale; P L Perot; J Piepmeier; V K Sonntag; F Wagner; J E Wilberger; H R Winn; W Young
Journal:  JAMA       Date:  1997-05-28       Impact factor: 56.272

9.  Methylprednisolone or tirilazad mesylate administration after acute spinal cord injury: 1-year follow up. Results of the third National Acute Spinal Cord Injury randomized controlled trial.

Authors:  M B Bracken; M J Shepard; T R Holford; L Leo-Summers; E F Aldrich; M Fazl; M G Fehlings; D L Herr; P W Hitchon; L F Marshall; R P Nockels; V Pascale; P L Perot; J Piepmeier; V K Sonntag; F Wagner; J E Wilberger; H R Winn; W Young
Journal:  J Neurosurg       Date:  1998-11       Impact factor: 5.115

10.  [Medical treatment of spinal cord injury in the acute stage].

Authors:  M E Petitjean; V Pointillart; F Dixmerias; L Wiart; F Sztark; P Lassié; M Thicoïpé; P Dabadie
Journal:  Ann Fr Anesth Reanim       Date:  1998
View more
  17 in total

1.  Alterations in chondroitin sulfate proteoglycan expression occur both at and far from the site of spinal contusion injury.

Authors:  Ellen M Andrews; Rebekah J Richards; Feng Q Yin; Mariano S Viapiano; Lyn B Jakeman
Journal:  Exp Neurol       Date:  2011-09-17       Impact factor: 5.330

2.  High dose methylprednisolone in the immediate management of acute, blunt spinal cord injury: what is the current practice in emergency departments, spinal units, and neurosurgical units in the UK?

Authors:  A E Frampton; C A Eynon
Journal:  Emerg Med J       Date:  2006-07       Impact factor: 2.740

Review 3.  The role of cyclic AMP signaling in promoting axonal regeneration after spinal cord injury.

Authors:  Sari S Hannila; Marie T Filbin
Journal:  Exp Neurol       Date:  2007-08-27       Impact factor: 5.330

4.  Emergency Neurological Life Support: Traumatic Spine Injury.

Authors:  Deborah M Stein; William A Knight
Journal:  Neurocrit Care       Date:  2017-09       Impact factor: 3.210

Review 5.  Emergency Neurological Life Support: Traumatic Spine Injury.

Authors:  Deborah M Stein; Jose A Pineda; Vincent Roddy; William A Knight
Journal:  Neurocrit Care       Date:  2015-12       Impact factor: 3.210

6.  An injectable thiol-acrylate poly(ethylene glycol) hydrogel for sustained release of methylprednisolone sodium succinate.

Authors:  Christopher D Pritchard; Timothy M O'Shea; Daniel J Siegwart; Eliezer Calo; Daniel G Anderson; Francis M Reynolds; John A Thomas; Jonathan R Slotkin; Eric J Woodard; Robert Langer
Journal:  Biomaterials       Date:  2010-09-28       Impact factor: 12.479

7.  Pediatric thoracic SCIWORA after back bend during dance practice: a retrospective case series and analysis of trauma mechanisms.

Authors:  Jian Ren; Gao Zeng; Yong-Jie Ma; Nan Chen; Zan Chen; Feng Ling; Hong-Qi Zhang
Journal:  Childs Nerv Syst       Date:  2017-04-04       Impact factor: 1.475

Review 8.  Translational spinal cord injury research: preclinical guidelines and challenges.

Authors:  Paul J Reier; Michael A Lane; Edward D Hall; Y D Teng; Dena R Howland
Journal:  Handb Clin Neurol       Date:  2012

9.  Effect of endogenous androgens on 17beta-estradiol-mediated protection after spinal cord injury in male rats.

Authors:  Supatra Kachadroka; Alicia M Hall; Tracy L Niedzielko; Sukumal Chongthammakun; Candace L Floyd
Journal:  J Neurotrauma       Date:  2010-03       Impact factor: 5.269

Review 10.  Chemokines as possible targets in modulation of the secondary damage after acute spinal cord injury: a review.

Authors:  Peter Gál; Petra Kravcuková; Michal Mokrý; Darina Kluchová
Journal:  Cell Mol Neurobiol       Date:  2009-04-11       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.